Renin Inhibitors
1 drugsAbout Renin
Renin is a key enzyme in the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure and electrolyte balance. As a result, it is a clinically validated drug target for cardiovascular diseases. Inhibition of Renin modulates the RAAS pathway, offering a direct approach to managing hypertension.
Renin is a clinically validated target, but there is currently no genetic evidence directly linking Renin to specific diseases. Its established physiological role in blood pressure regulation underscores its importance as a therapeutic target. Further research could expand therapeutic applications within the cardiovascular area.
There is one FDA-approved drug, Aliskiren hemifumarate, targeting Renin for cardiovascular indications. This drug is a small molecule approved in 2019 by PH HEALTH. Further development of novel drug modalities could expand therapeutic options.
Top Renin Drugs
PH HEALTH is the only company with an approved Renin-targeting drug.
Low competition suggests an opportunity for new entrants, but also indicates potential market challenges.
Renin Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Renin, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Renin Clinical Trials 55 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Renin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 | 100% |
| Phase 2 | 7 | 2 | 4 | 1 | 33% |
| Phase 3 | 12 | 10 | 2 | 0 | 83% |
| Phase 4 | 32 | 22 | 10 | 0 | 69% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Renin Drug Approval Timeline (2019 - 2019)
The first and most recent drug approval was Aliskiren hemifumarate in 2019.
Recent entry suggests renewed interest, but a single approval indicates potential saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 28 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Renin. A trial counts if an approved drug acting on Renin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.